Skip to main content

Keros Therapeutics, Inc.

KROS
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001664710

In the last 90 days, Keros Therapeutics, Inc. insiders filed 2 open-market purchases and 4 sales; 132 institutions reported holding it in 13F filings for Q2 2026, worth $198.6M in total; no superinvestor holds it.

Q2 2023 vs. Q1 2023

How the institutions holding Keros Therapeutics, Inc. changed between Q1 2023 and Q2 2023.

All holders in Q2 2023All holders in Q1 2023

13F holders of KROS: Q1 2023 compared with Q2 2023
MeasureQ1 2023Q2 2023Change
Holders129123−6
Shares22.0M22.4M+420.0K (+1.9%)
Value$937.0M$901.0M−$36.0M (−3.8%)

New holders (14)

Institutions that held Keros Therapeutics, Inc. at the end of Q2 2023 but not at the end of Q1 2023.

Institutions new to KROS in Q2 2023
InstitutionSharesValue% of portfolio
Braidwell LP1,143,865$46.0M1.50%
Dimensional Fund Advisors LP58,766$2.36M0.00%
Balyasny Asset Management LLC10,323$414.8K0.00%
Virtu Financial LLC8,708$350.0K0.03%
Campbell & CO Investment Adviser LLC7,745$311.2K0.06%
Cresset Asset Management, LLC7,682$308.7K0.00%
Jump Financial, LLC7,283$292.6K0.01%
Healthcare of Ontario Pension Plan Trust Fund7,000$281.3K0.00%
BIT Capital GmbH6,962$279.7K0.03%
Meitav Dash Investments Ltd1,597$63.8K0.00%
Advisor Group Holdings, Inc.884$35.5K0.00%
HighMark Wealth Management LLC75$3.01K0.00%
CWM, LLC33$1.00K0.00%
Quadrant Capital Group LLC6$2420.00%

Sold out (20)

Institutions that held Keros Therapeutics, Inc. at the end of Q1 2023 and filed for Q2 2023 without it.